TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06348082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy for insomnia (MBTI)
Description: MBTI will be administered in 8 weekly sessions. Session 1 consists of introductions and an overview. Subsequent sessions consist of mindfulness concepts/practice and behavioral strategies for sleep. Each session will begin with guided formal meditation followed by discussion. Mindfulness practice (at home) expectations are 30-45 minutes of meditation/day at least 5 days during the period of the intervention, followed by 20 minutes/day until the final follow-up assessment (at 16 weeks). Mindfulness concepts: Overview of Mindfulness, Mindfulness of the Body, Obstacles to Mindfulness,Working with Difficult Emotions, Cultivating Positive Emotions, Working with Difficult Thoughts, Mindful Interactions.
Study: NCT05406856

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation therapy: IMRT/VMAT
Description: EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy: IMPT
Description: EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The standard chemotherapy regimen is weekly cisplatin (40 mg/m2) for 5 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: The standard chemotherapy regimen is weekly cisplatin (40 mg/m2) for 5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy is performed using a high-dose rate (HDR) after loading system to deliver a boost to any residual tumor and the cervix. Brachytherapy dose is (21-) 28 Gy in fractions of 7 Gy specified at 100% isodose around the high-risk CTV, according to the EMBRACE-II prescription protocol. The aim is to reach an equivalent dose in 2 Gy fractions including EBRT (EQD2_D90) of the high-risk CTV between 90-95 Gy, using MRI-guided adaptive brachytherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Brachytherapy is performed using a high-dose rate (HDR) after loading system to deliver a boost to any residual tumor and the cervix. Brachytherapy dose is (21-) 28 Gy in fractions of 7 Gy specified at 100% isodose around the high-risk CTV, according to the EMBRACE-II prescription protocol. The aim is to reach an equivalent dose in 2 Gy fractions including EBRT (EQD2_D90) of the high-risk CTV between 90-95 Gy, using MRI-guided adaptive brachytherapy.
Study: NCT06454526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Program
Description: Mindfulness Based Program is an 8-week program with a total of 25 hours. The program, which consists of lectures, meditation and sharing areas, consists of the following topics: Six Senses and Pleasure, Mindfulness and Mind, Get Out of the Head and Enter the Body, Compassion, Meeting Challenges, Stress Reactions and Healing, Retreat Silence Day, Neuroplasticity and the Changing Brain and Wise Living.
Study: NCT06339398

Intervention type: BEHAVIORAL
Intervention: Aerobic exercise
Description: Standardized volume of aerobic exercise, measured as METs-minutes/week

Intervention type: BEHAVIORAL
Intervention: Aerobic exercise
Description: Standardized volume of aerobic exercise, measured as METs-minutes/week
Study: NCT05791279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart age
Description: information about their ECG-based Heart-Age and the Heart Age gap, i.e. the difference between chronological and ECG-based Heart Age.
Study: NCT05934266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of n-hexyl cyanoacrylate for mesh fixation
Description: Mesh fixation with tissue adhesive (n-hexyl cyanoacrylate) in open hernia repair
Study: NCT06439030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery program
Description: The practices included in the program are: Cinema Film Screening and Emotion/Thought Sharing, Laughter Yoga Practice, Stress Coping Techniques Training, Progressive Relaxation, Loss/Mourning Process Training, Expressive Art Therapy Practice, Healthy Lifestyle Behaviors Training.
Study: NCT06375304

Intervention type: DRUG
Group type: OTHER
Intervention: B/F/TAF
Description: The intervention consists of prescribing B/F/TAF to eligible ART-experienced migrant patients, free of charge, in four care settings, for 12 months (48 weeks).~B/F/TAF is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements.
Study: NCT05768490

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brain radiotherapy
Description: Patients were randomly divided into two groups, experimental group (early intervention group of brain radiotherapy) : the brain radiotherapy started within 1 month of TKI treatment, the brain radiotherapy here specifically refers to stereotactic radiotherapy; Control group (brain radiotherapy late intervention group) : Brain radiotherapy was given within 3 months after brain progression during TKI treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: almonertinib po 110mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: almonertinib po 110mg QD
Study: NCT06066892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impression techniques
Description: 3 types of impression techniques for all on four

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impression techniques
Description: 3 types of impression techniques for all on four

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impression techniques
Description: 3 types of impression techniques for all on four
Study: NCT06773416

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health
Description: Participants in Group 1 will receive CPAP therapy immediately upon enrollment alongside web-based sleep education through the Brain Health Pro (BHP) platform. The CPAP intervention includes a study-provided auto-titrating device, in-person mask fitting, and ongoing support from a study sleep technologist. Adherence will be monitored via remote data uploads. The BHP platform is a 45-week web-based formal educational program program designed to increase dementia literacy, foster engagement, and convey best available evidence for lifestyle changes that can mitigate dementia risk. This combined approach ensures simultaneous initiation of CPAP and educational reinforcement to optimize adherence and cognitive outcomes.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Delayed CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health
Description: Participants in Group 2 will begin with 4 months of BHP web-based sleep education before adding CPAP therapy for the remaining 4 months. CPAP setup and support are identical to the Early CPAP group. Participants in Group 2 will experience procedure similar to current clinical practices.
Study: NCT06771518

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Thoracic radiotherapy using 4D technique by irradiating the initial sites of disease (primary tumor and involved hilo-mediastinal lymph nodes). The treatments must be provided with the modulated intensity technique (IMRT or VMAT), treatments with conformal technique (3DCRT) are not permitted, where necessary, the Simultaneous Integrated Boost (SIB) technique can be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg e.v. q21
Description: Radiotherapy treatment associated with Atezolizumab 1200 mg i.v. q21 administered according to clinical practice
Study: NCT06773117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Susu Xiao'er Zhike Granules
Description: High dose Susu Xiao'er Zhike Granules 1 bag(7g granule per bag,contains 20.25 g crude herbs), twice a day for five days

Intervention type: DRUG
Group type: OTHER
Intervention: Extremely-low dose Susu Xiao'er Zhike Granules
Description: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag (7g granule per bag,contains 1.01 g crude herbs), twice a day for five days
Study: NCT06220656

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Local anesthetic is usually given and a small needle is used to take cells from the thyroid under ultrasound guidance through several 'passes' and placed into specialized media for pathology evaluation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active Monitoring
Description: Ultrasound and a check-up at 6 months. Depending on ultrasound results, either biopsy and further care (as for the treatment arm called 'biopsy'), or continue with active monitoring.
Study: NCT05666778

Intervention type: DEVICE
Group type: OTHER
Intervention: Menstrual Cup
Description: Menstrual cups are inserted vaginally to collect menstrual flow, with some designed especially for use during intercourse, which will be used in this study. Medical devices registered with the U.S. FDA, a reusable silicon cup can last up to 10 years, is cost-effective, and has reduced environmental impact.
Study: NCT06228456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60mg
Description: Patients in the ticagrelor arm will receive a 180 mg loading dose of ticagrelor followed by ticagrelor 60 mg bid maintenance dose for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients in the clopidogrel arm will continue to receive clopidogrel 75 mg/daily for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
Study: NCT06773507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BC008-1A 900mg
Description: BC008-1A 900mg will be administered once every 3 weeks until disease progression occurs, or intolerable toxicity develops, or they are lost to follow-up, or withdraw their informed consent, or start a new anti-tumor treatment, or the investigator decides to withdraw them based on the subject's benefit situation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BC008-1A 1200mg
Description: BC008-1A 1200mg will be administered once every 3 weeks until disease progression occurs, or intolerable toxicity develops, or they are lost to follow-up, or withdraw their informed consent, or start a new anti-tumor treatment, or the investigator decides to withdraw them based on the subject's benefit situation.
Study: NCT06501053

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 45/50 Gy (1.8/2 Gy/fraction/5 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: 25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Contact x-ray brachytherapy
Description: 90Gy/3 fractions/4 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Contact x-ray brachytherapy
Description: 90Gy/3 fractions/4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Capecitabine (900 mg/m2 bid, on radiation days)
Study: NCT05821140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental treatment for global oral rehabilitation
Description: dental treatment can include conservative, orthodontic, prosthetic or surgical procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental treatment for global oral rehabilitation
Description: dental treatment can include conservative, orthodontic, prosthetic or surgical procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental treatment for global oral rehabilitation
Description: dental treatment can include conservative, orthodontic, prosthetic or surgical procedures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral health check up
Description: regular preventive follow-up visit (every 6 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral health check up
Description: regular preventive follow-up visit (every 6 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral health check up
Description: regular preventive follow-up visit (every 6 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral health check up
Description: regular preventive follow-up visit (every 6 months)
Study: NCT04640766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRISM
Description: The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on no-consecutive days. Each session will last approximately 30 minutes.
Study: NCT05536323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam bolus
Description: Remimazolam bolus 0.14-0.33 mg/kg 0.25-0.33 mg/kg, \<40 years 0.19-0.25 mg/kg, 60-80 years 0.14-0.19 mg/kg, \>80 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam continuous
Description: Remimazolam 12 mg/kg/hr
Study: NCT05524545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept
Description: Fusion protein that blocks CD47-SIRPalpha pathway

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Nectin-4 directed antibody and microtubule inhibitor conjugate
Study: NCT04951076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC210
Description: BNC210 900 mg twice daily (b.i.d.) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily (b.i.d.) for 12 weeks
Study: NCT06214260

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood sample
Description: Peripheral blood will be collected with a 10 ml Ethylenediaminetetra acetic acid (EDTA) tube before surgery during menstrual phase. Additionally, participants will be asked with an interview on demographic, surgical, medical, obstetric, gynecological, contraceptive and medication use history which is validated by Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHect). Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood sample
Description: Peripheral blood will be collected with a 10 ml Ethylenediaminetetra acetic acid (EDTA) tube before surgery during menstrual phase. Additionally, participants will be asked with an interview on demographic, surgical, medical, obstetric, gynecological, contraceptive and medication use history which is validated by Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHect). Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Menstrual Blood sample
Description: 5ml menstrual blood will be collected before surgery by the women herself. Additionally, participants will be asked with an interview on demographic, surgical, medical, obstetric, gynecological, contraceptive and medication use history which is validated by Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHect). Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Menstrual Blood sample
Description: 5ml menstrual blood will be collected before surgery by the women herself. Additionally, participants will be asked with an interview on demographic, surgical, medical, obstetric, gynecological, contraceptive and medication use history which is validated by Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHect). Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).
Study: NCT01560065

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: myo-inositol + folic acid
Description: 4000mg myo-inositol + 400 µg folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: myo-inositol + folic acid
Description: 4000mg myo-inositol + 400 µg folic acid
Study: NCT04787965

Intervention type: DRUG
Intervention: Opicapone
Description: Opicapone as adjunctive treatment to levodopa/carbidopa over a 6-month period
Study: NCT04864873

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Metagenomic next generation sequencing using Oxford Nanopore
Description: See previous.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard microbiological diagnostic pathway
Description: See previous.
Study: NCT05620355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG2109
Description: BG2109 100mg film coated tablet for oral administration once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG2109
Description: BG2109 100mg film coated tablet for oral administration once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BG2109
Description: Placebo for BG2109 100mg tablet for oral administration once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BG2109
Description: Placebo for BG2109 100mg tablet for oral administration once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for add-back therapy
Description: Placebo for add-back therapy tablet for oral administration once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for add-back therapy
Description: Placebo for add-back therapy tablet for oral administration once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back therapy
Description: Estradiol 1 mg / Norethindrone Acetate 0.5 mg for oral administration once daily.
Study: NCT06770933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-01
Description: There is no physical difference in VX-01 and the placebo. The only difference lies in active ingredient found in VX-01, which is the compound that will be evaluated in the course of this study.
Study: NCT04647292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration
Description: A medication algorithm based on the SPRINT trial protocol will be provided for patients in the home blood pressure measurement arm. The final choice and dose of antihypertensive treatment(s) will be at the discretion of the treating clinicians. If no contra-indications, indapamide or other thiazide diuretic and/or angiotensin-converting enzyme (ACE) inhibitor (perindopril or other) will be encouraged as initial therapy, with long-acting calcium-channel antagonists (eg.amlodipine) encouraged as third-line therapy.~Patients will have their home blood pressure monitoring diary reviewed by the study team. If SBP is out of the allocated target range, a prescription to titrate antihypertensive medication will be sent to the patient at least monthly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Blood Pressure Management with Antihypertensives
Description: Participants in the standard of care arm will receive antihypertensive therapy at the physician's discretion to the same treatment target of SBP \<130mmHg.
Study: NCT05181995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-783
Description: NYX-783

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 50 mg NYX-783
Study: NCT06541405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK520
Description: The number of NK520 cell infused for each dosing should be calculated base on the body weight of subject. NK520 will be administered through intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK520
Description: The number of NK520 cell infused for each dosing should be calculated base on the body weight of subject. NK520 will be administered through intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK520
Description: The number of NK520 cell infused for each dosing should be calculated base on the body weight of subject. NK520 will be administered through intravenous infusion.
Study: NCT06341673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcutaneous Electrical Nerve Stimulation (TENS)
Description: For active group: TENS is to be used to stimulate tibial Nerve at medial aspect of the foot. The stimulation is proved by flexion of the big toe (motor response) and/or tingling sensation of ipsilateral sole of foot (sensory response) by raising the current amplitude, mA, intensity. Increasing the intensity above sensory threshold is recommended but should not be painful

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation (TENS)
Description: TENS on the lateral side of the foot, the negative electrode on the top of the foot just above the small toe for conduction and the positive electrode on the bottom of below the smallest toe to avoid the tibial nerve and relevant cutaneous nerves. Participants will be instructed to raise up the intensity until the first and slight tingling sensation on the sole of the foot or toe
Study: NCT05926310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TWIICE Rise
Description: TWIICE Rise is a lower-limb overground robotic exoskeleton intended for patients with spinal cord injury (SCI).~TWIICE Rise is intended to perform ambulatory functions in rehabilitation institutions, home, or community environment under the supervision of a specially trained coach.
Study: NCT05236803

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Testing of general motor skills, fine motor skills and occulomotricity
Description: Recording of participant's performance during eye, fine motor and gross motor tests; Children's gross motor skills will be assessed through a biomechanical analysis.~Eye movements will be recorded using the eye-tracking system (Tobii Pro TX300). The technique used is the corneal reflection technique.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Passing self and hetero questionnaires.